The role of FSH in body composition in hematopoietic cell transplant recipients

Pediatr Transplant. 2022 Feb;26(1):e14130. doi: 10.1111/petr.14130. Epub 2021 Sep 5.

Abstract

Background: Childhood cancer survivors who received a hematopoietic cell transplantation (HCT) are at increased risk for follicle-stimulating hormone (FSH) abnormalities, which may have a significant negative impact on bone health and body composition. This study's purpose was to examine FSH and body composition in HCT recipients, non-HCT recipients and healthy controls.

Methods: The study included HCT recipients (n = 24), non-HCT recipients (n = 309), and a control group of healthy siblings (n = 211) all aged 9-18 years. A fasting blood sample was collected to measure FSH. All participants underwent a dual X-ray absorptiometry scan to assess total and regional percent fat, lean mass (LM), fat mass (FM), bone mineral content (BMC), bone mineral density (BMD), and visceral adipose tissue (VAT) mass.

Results: FSH was significantly higher in HCT recipients compared to non-HCT recipients and healthy controls. HCT recipients had significantly lower total body weight, total LM, arm and leg LM, BMC and BMD compared to non-HCT recipients and healthy controls (p < .05). Non-HCT recipients had significantly higher total, trunk, android, gynoid, arm and leg FM compared to healthy controls. Also, healthy controls had significantly lower VAT mass compared to non-HCT recipients.

Conclusions: This study's results show that HCT recipients have significant reductions in BMD, worse body composition, and abnormal FSH levels compared to non-HCT recipients and healthy controls.

Keywords: %BF; BMD; FM; LM; VAT.

MeSH terms

  • Adolescent
  • Biomarkers / blood
  • Body Composition*
  • Bone Density*
  • Case-Control Studies
  • Child
  • Female
  • Follicle Stimulating Hormone / blood*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Linear Models
  • Male

Substances

  • Biomarkers
  • Follicle Stimulating Hormone